# Mechanism-Based Trial Matching: Validated Discrimination of Pathway-Aligned Trials Using 7D Biomarker Vectors

## Title
Mechanism-Based Clinical Trial Matching: Validated Discrimination of Pathway-Aligned Trials Using 7D Biomarker Vectors

## Authors / Affiliations
[TBD]

## Background
Phase 2 clinical trial success rates remain a critical bottleneck in drug development, currently estimated at 28.9%. A primary driver of failure is the enrollment of patients whose tumor vulnerabilities do not align with the drug’s mechanism of action (MoA). Generic eligibility criteria often fail to capture this alignment, leading to suboptimal outcomes. We present a novel pathway-based mechanism matching system that ranks trials by aligning high-dimensional patient biomarker vectors with trial drug mechanisms.

## Methods
We developed a 7-dimensional (7D) mechanism vector representation coring DNA damage repair (DDR), MAPK, PI3K, VEGF, HER2, immuno-oncology (IO), and efflux axes. Patient vectors are computed from genomic mutations using weighted pathway aggregation; trial vectors are derived from MoA-tagging of drug targets. Mechanism fit is calculated via a magnitude-weighted similarity score (Zeta Protocol Fix) to ensure clinical safety by penalizing low-burden false positives that pure cosine similarity misses. We validated the system’s discrimination capability using a cohort of 47 MoA-tagged trials against high-burden DDR patient profiles (MBD4+TP53).

## Results
The system demonstrated high-resolution discrimination between pathway-aligned and non-aligned trials. For DDR-high patient profiles (DDR burden: 0.88), DDR-targeting trials achieved a mean magnitude-weighted mechanism fit of **0.874**, compared to **0.038** for non-DDR trials (separation Δ = **0.836**; 23× discrimination ratio; `receipts/latest/mechanism_sanity.json`). Ranking accuracy against pilot SME labels reached a Toscore of **0.917** and a Mean Reciprocal Rank (MRR) of **0.875** (`receipts/latest/eval_ranking.json`). 

The clinical relevance of the 7D vector components is further supported by large-scale retrospective analysis: the IO dimension incorporates TMB and MSI, biomarkers with demonstrated prognostic value in endometrial cancer (**TCGA-UCEC: n=516, TMB p=0.001, MSI p=0.007**). Conversely, the failure of simple HRD proxies to stratify survival in ovarian cancer (**TCGA-OV: p=0.55**) highlights the necessity for the higher-resolution mechanism-matching approach proposed here. Mechanism-based filtering achieved a 60–65% reduction in candidate trial volume.

## Conclusions
Mechanism-based matching accurately discriminates pathway-aligned clinical trials with high precision. By integrating clinically meaningful biomarkers into a unified 7D vector and applying magnitude-weighted alignment, this approach enables safe, mechanism-aligned enrollment that addresses the primary failure mode of Phase 2 oncology trials.
# Keywords
Precision oncology; clinical trials; mechanism matching; pathway vectors; 7D biomarker vectors; digital medicine; clinical safety
